硝酸甘油与新活素治疗急性失代偿性充血性心力衰竭临床疗效

急性失代偿性充血性心力衰竭（ADHF）是突然出现的心力衰竭症状及体征的加重及恶化，其发病凶险，若不及时处理，其病死率较高。新活素，即重组人脑利钠肽（rhBNP），对急性失代偿性充血性心力衰竭全身临床症状及呼吸困难情况均具有较好的改善作用。

新活素联合地高辛对扩张型心肌病心衰患者心功能及NT-proBNP影响研究

目的:探讨新活素联合地高辛对扩张型心肌病心衰患者心功能及氨基末端B型钠尿肽前体(NT-proBNP)影响。方法:扩张型心肌病(DCM)心衰患者104例采用随机数字法将其分为对照组和观察组,每组各52例。对照组患者口服地高辛治疗,在此基础上,观察组患者静脉滴注新活素治疗。比较两组患者的治疗总有效率,同时比较治疗前后的心功能指标和血浆NT-proBNP水平。结果:观察组患者治疗总有效率为92.30%,明显高于对照组的78.85%(χ~2=5.28,P=0.02);治疗后,观察组的LVEF、SV、CI及CO均明显高于对照组(P<0.01),血浆NT-proBNP水平明显低于对照组(t=11.68,P<0.01)。结论:新活素联合地高辛对扩张型心肌病心衰的临床疗效显著,能够有效改善心脏结构及功能,降低血浆NT-proBNP水平,提高预后质量。

复方丹参滴丸联合新活素对充血性心力衰竭LvEF及NT-proBNP的影响

目的:探讨复方丹参滴丸联合新活素对充血性心力衰竭LVEF及NT-proBNP的影响。方法:对照组给予硝普钠治疗,治疗组给予复方丹参滴丸联合新活素治疗。结果:对照组总有效率为60.8%,治疗组总有效率89.2%,治疗组临床疗效显著优于对照组(P<0.05)。治疗后,治疗组患者LVEF为59.2±8.9,显著高于对照组患者39.6±8.2,差异具有统计学意义(P<0.05)。治疗组患者治疗后NT-proBNP为3761±240.56,显著低于对照组患者治疗后的4123±283.4,差异具有统计学意义(P<0.05)。结论:复方丹参滴丸联合新活素治疗CHF可有效改善患者症状,提高LVEF水平,降低NT-proBNP水平,疗效确切,值得应用。

Innovation in the Manufacturing Sector： The Case of Serbia

The paper presents the results of research on innovation activities of manufacturing firms in Serbia. In order to answer the question how innovation takes place in one transition country, key influencing factors were identify （i.e., firm＇s size, age, ownership, industry sector, personnel qualifications and experience）. Based on the analysis of a sample comprising 73 firms, the study tried to highlight certain innovation barriers, which may have a negative impact on the total efficiency of economic performance, and growth and development of manufacturing firms in Serbia. Comparing overall innovation activities of Serbian firms to the other transition countries, it can be concluded that majority of the fhnns had innovation performances below the level EU-27. This study draws out the potential contributions to existing literature of managing innovation in Serbia.